GlassScriptPhysician profile
Rachel E Soles
NPI 1033480769
$617.63
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.20 · 2022: $200 · 2024: $40.50 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $120.21 | 2025 | Brixadi |
| Tandem Diabetes Care, INC. | $91.78 | 2022 | |
| Alkermes, INC. | $75.47 | 2025 | Aristada, Vivitrol, Lybalvi |
| Janssen Pharmaceuticals, INC | $54.64 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $35.34 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Insulet Corporation | $34.34 | 2022 | |
| Dexcom, INC. | $32.23 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $31.55 | 2022-2024 | |
| Abbvie INC. | $30.90 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $22.50 | 2022 | |
| Glaxosmithkline, LLC. | $22.48 | 2025 | Trelegy Ellipta |
| Cequr Corporation | $22.10 | 2022 | |
| Indivior INC. | $15.60 | 2025 | Sublocade |
| Orexo US, INC. | $14.55 | 2025 | Zubsolv |
| Lilly USA, LLC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Soles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.